Send to

Choose Destination
See comment in PubMed Commons below
Asian J Androl. 2012 Nov;14(6):813-4. doi: 10.1038/aja.2012.89. Epub 2012 Aug 27.

Long-term cross-sex hormone treatment is safe in transsexual subjects.

Author information

  • 1Center for Protection of Sexual Health, Physiopathology of Reproduction and Gynecology, University of Bologna and S. Orsola-Malpighi Hospital, Bologna 40138, Italy.


The European Journal of Endocrinology recently published a paper (Asscheman et al.) presenting mortality data from more than a thousand transsexuals followed for a median time of 18 years and who had undergone previous or were currently on long term cross-sex hormonal treatment. Transsexualism is a rare condition and in scientific literature there are few reports on the long-term safety of different treatment protocols and on the physical and psychological outcomes of medical treatments. The safety of long-term high doses oestrogen or testosterone in subjects of the opposite sex has been debated and data on long term effects are scant at best. The Asscherman paper therefore represents a very important and reassuring reference for professionals working in this field suggesting that mortality is increased among transsexuals although due to causes unrelated to cross sex replacement therapy. These results will benefit the care and treatment of these subjects.

Publication Types

Publication Types

PubMed Commons home

PubMed Commons

How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Medknow Publications and Media Pvt Ltd Icon for PubMed Central
    Loading ...
    Write to the Help Desk